Brief: Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
17/04/2024 13:27
April 17 (Reuters) - Celldex Therapeutics Inc CLDX.O :
* CELLDEX ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2
STUDY OF
BARZOLVOLIMAB IN PATIENTS WITH CHRONIC INDUCIBLE URTICARIA
Source text for Eikon: ID:nGNXbgb5ct
Further company coverage: CLDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials